Multiple Myeloma

A supplemental Biologics License Application (sBLA) has been initiated with the FDA for daratumumab (Darzalex) for use in combination with lenalidomide (Revlimid) and dexamethasone (DRd) for the treatment of certain patients with multiple myeloma.

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the progress that has been made in transplant-ineligible patients with multiple myeloma.

Maria-Victoria Mateos, MD, PhD, discusses the updated findings from the ALCYONE trial in patients with newly diagnosed multiple myeloma.

Robert M. Rifkin, MD, highlights the results of a trial evaluating the safety of split-dosing administration of daratumumab in patients with multiple myeloma.

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Hospital, discusses the treatment of patients with penta-refractory multiple myeloma.

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses an investigational antibody-drug conjugate (ADC) in multiple myeloma.

The development of cancer treatments and diagnostic tools using CRISPR/Cas9 and other gene-editing technology is a promising area of research in the United States, although the field is moving into human studies at a relatively slow pace.

Investigators are taking a personalized approach to treating patients with multiple myeloma by introducing novel agents in combination with backbone chemotherapies, based on patients’ individual genetic profiles.